Lower BP target showed no clear difference in total mortality compared with standard BP target (high certainty).
Lower BP target showed no clear difference in total serious adverse events№ of participants: 18165(6 RCTs) compared with standard BP target (moderate certainty).
Lower BP target may leads to lower myocardial infarction№ of participants: 38,198(8 RCTs) compared with standard BP target (low certainty).
Lower BP target showed no clear difference in stroke№ of participants: 37,087(7 RCTs) compared with standard BP target (low certainty).
Lower BP target may leads to lower congestive heart failure№ of participants: 15,859(5 RCTs) compared with standard BP target (low certainty).
Lower BP target may leads to higher other serious adverse events compared with standard BP target (low certainty).
Uric acid‐lowering drug showed no clear difference in adverse events (withdrawals due to side effects) compared with placebo (low certainty).
Lower blood pressure targets showed no clear difference in total mortality compared with standard blood pressure targets (moderate certainty).
Lower blood pressure targets showed no clear difference in total serious adverse events compared with standard blood pressure targets (low certainty).
Lower blood pressure targets showed no clear difference in total cardiovascular events compared with standard blood pressure targets (low certainty).
Lower blood pressure targets showed no clear difference in cardiovascular mortality compared with standard blood pressure targets (moderate certainty).
It is very uncertain whether lower blood pressure targets changes participant withdrawals due to adverse effects compared with standard blood pressure targets (very low certainty).
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in all‐cause mortality compared with lower BP target (< 140/90 mmHg) (low certainty).
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in stroke compared with lower BP target (< 140/90 mmHg) (low certainty).
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in cardiovascular serious adverse events compared with lower BP target (< 140/90 mmHg) (low certainty).